CDER News Along the Pike
September 15, 2006
Volume 12, Issue 1
Back to Contents
Print version: [Entire
issue] [Only this article]
Pharm/Tox Corner
Fall Retreat
focuses on nanotechnology, tissue cross-reactivity studies,
guidances on National Formulary reference terminology, statistical
consults for carcinogenicity studies, Pharm/Tox Web Page, Education
Subcommittee updates
By Gary P. Bond, Ph.D., DABT
The pharm/tox
semi-annual scientific retreat held in September gathered reviewers
within CDER. The retreat started by opening remarks from chair
Haleh Saber-Mahloogi, Ph.D., and John Leighton Ph.D., DABT.
David Jacobson-Kram, Ph.D., DABT, the associate director for
pharm/tox in the Office of New Drugs, welcomed all to the meeting.
The fall
retreat focused on:
-
Nanotechnology.
-
Tissue cross-reactivity studies.
-
Guidances on national formulary reference terminology.
-
Statistical consults for carcinogenicity studies.
-
The Pharm/Tox intranet site.
Nanotechnology
FDA’s
activities dealing with the potential of nanotechnology on the
products it regulates were discussed by Nakissa Sadrieh, Ph.D.,
associate director for research policy and implementation in the
Office of Pharmaceutical Science and Steve Stern, Ph.D., from
the National Cancer Institute’s Nanotechnology Characterization Lab.
[Nanotechnology
creates small materials at the scale of molecules by manipulating
single atoms. A molecule’s size is measured in nanometers or
billionths of a meter.]
FDA is engaged
both on the scientific level and on the regulatory and policy level
to address the possible challenges that products utilizing
nanotechnology present:
Scientifically, FDA is involved in a number of nanotechnology
research projects.
On
the regulatory and policy level, FDA participates in various
committees to coordinate the activities and policies of the
government regulatory agencies.
At FDA, a
NanoTechnology Interest Group, or NTIG, includes representatives
from all FDA centers and all FDA offices that report directly to the
Office of the Commissioner. Also, the center have established
multidisciplinary working groups.
While the
impact of nanotechnology and its applications is
expected
to be in the future, FDA has already approved many products with
particle dimensions in the nanometer range. Specifically, there are
imaging agents that have been on the market for a number of years
with particles that are smaller than 100 nanometers. There are also
reformulated products that contain nanoparticles of previously
approved products, in order to improve product performance.
Similarly, there are sunscreens and cosmetics where the particle
size of titanium dioxide and zinc oxide are reported to be smaller
than 100 nanometers.
Some novel
platforms being developed, such as the multifunctional dendrimers,
may require a multifaceted approach towards their review and
evaluation. Previously approved products with particles in the
nanometer range were not considered to be nanotechnology products.
They were, therefore subject to the same testing requirements as all
other products. However, we expect some of these novel products
utilizing nanotechnology will be combination products (i.e.,
drug-device, drug-biologic, or device-biologic).
While sponsors
of nanotechnology products will be subject to the same testing
requirements as non-nanotechnology products, there may be challenges
before commercialization. Specifically, there will need to be an
understanding of the physical and chemical parameters that are
crucial to product performance. Additionally, appropriate test
methods and specifications to control the product or the
manufacturing processes will need to be developed.
Guidance/MaPP
Updates
National
Drug Formulary Reference Terminology MaPP and Guidance.
John Leighton, Ph.D. DABT, a supervisory pharmacologist from
the Division of Drug Oncology Products, discussed the draft guidance
and MaPPs on the initiative for pharmacologic classification for the
highlights section of labels. The guidance provides industry and our
reviewers direction to access the National Drug File Reference
Terminology, which was designed by the Veterans Administration to
provide consistency in drug terminology use in healthcare.
MaPPs
associated with the proposed guidance are intended to guide
pharmacology and toxicology reviewers through the process of
requesting new terminology if the appropriate terminology for
pharmacologic classification for new molecular entities is not
available. Terminology can be accessed publicly through the National
Cancer Institute’s Terminology Browser at
http://nciterms.nci.nih.gov/NCIBrowser/Startup.do,
and several examples were provided to retreat attendees.
Statistical
Consults for CARC Studies.
Abby Jacobs, Ph.D., Assoc. Dir. Pharm/Tox ONDIO, talked about
statistical consults for carcinogenicity studies. She emphasized the
importance of good communication between the pharmacology/toxicology
reviewer and the reviewing statistician. The talk covered the
preliminary review by the pharmacology/toxicology reviewer, what to
convey to the statistical reviewer, what to look for in the
statistician’s review and the importance of feedback to the
statistician.
Tissue
Cross-Reactivity
Tissue
cross-reactivity studies for potential therapeutic antibodies that
are included as part of the Pharmacology/Toxicology Sections of INDs
were discussed by Joan Wicks, DVM, Ph.D., DACVP; Shari Price-Schiavi,
DVM, Ph.D., DACVP; and Jennifer Rojko, DVM, Ph.D., DACVP
of Charles River Laboratories, Pathology Associates, Molecular and
Immunopathology Division.
The objectives
of these studies are to identify expected and unexpected tissue
binding (or cross-reactivity) of antibodies (test articles) in human
and animal tissues and to evaluate the relevance of a given species
for use in toxicity studies with that antibody.
Most potential
therapeutic antibodies are chimeric, humanized or human. For these
test articles, the most common staining methods include avidin-biotin
complex (ABC) for a biotinylated test article, tertiary antibody
detection for a FITC (or otherwise) labeled test article, or
precomplexing with a labeled anti-human IgG for an unlabeled test
article.
For all test
articles, a species, isotype and, where appropriate, similarly
labeled negative control antibody must be included to aid in
evaluation of specificity of any staining observed with the test
article. An assay control should also be included to define any
background staining from the detection reagents themselves.
An appropriate
positive control material may include one of the following: a tissue
element or cell line known to express the target antigen, sepharose
or agarose beads coated with the target antigen, or the target
antigen spotted and cross-linked onto UV-resin slides. An
appropriate negative control material may include a tissue element
or cell line that does not express the target antigen, beads coated
with an irrelevant antigen, or an irrelevant antigen spotted and
cross-linked to UV-resin slides.
Specific
reactions of the test article with the positive control material and
the lack of specific reactivity with the negative control material,
as well as lack of reactivity of the negative control antibody
demonstrate the sensitivity, specificity and reproducibility of the
assay. In a typical cross-reactivity study, a staining method most
appropriate for the test article is developed. In a typical 36 or 37
tissue cross-reactivity study, cryosections of normal human (3
unrelated donors) and/or animal (2 or 3 unrelated donors) tissues
are stained.
The slides are
evaluated first to see if the tissue is adequate and normal. Any
staining observed is judged specific (CDR mediated) or nonspecific
(non-CDR mediated) by comparison to the corresponding control slides
and by the nature of the staining. Any specific staining is judged
to be either an expected or unexpected reactivity based upon known
expression of the target antigen in question. Any staining judged
specific is scored for intensity, frequency, and staining affinity
(where appropriate). A report containing a summary, introduction,
materials and methods, results, and discussion is prepared and
submitted to the Sponsor.
Regulatory
Stance on Mutagenesis and Carcinogenesis.
Ed Matthews.
Ph.D. and Joe Contrera, Ph.D.,
made a presentation entitled “A Retrospective Analysis of Genetic
Toxicity, Reproductive Toxicity, and Carcinogenicity Data:
Identification of Carcinogens Using Biomarkers and In Silico
Methods.” Both are from Office of Pharmaceutical Science. Dr.
Matthews is from Science and Research Staff, and Dr. Contrera heads
Informatics and Computational Safety Analysis Staff.
The subject
matter was based on two reports that have been accepted for
publication in Regulatory Toxicology and Pharmacology in 2006
titled “An Analysis of Genetic Toxicity, Reproductive and
Developmental Toxicity” and “Carcinogenicity Data: I.
Identification of Carcinogens Using Surrogate Endpoints”
and “II.
Identification of Genotoxicants, Reprotoxicants, and Carcinogens
Using In Silico Methods.”
The first
article is a retrospective analysis of standard genetic toxicity (genetox)
tests, reproductive and developmental toxicity (reprotox) studies
and rodent carcinogenicity bioassays (rcbioassay). The study was
performed to identify the genetox and reprotox endpoints whose
results best correlate with rcbioassay observations. A database of
7,205 chemicals with genetox (n=4961), reprotox (n=2173) and
rcbioassay (n=1442) toxicity data was constructed; 1,112 of the
chemicals have both genetox and rcbioassay data and 721 chemicals
have both reprotox and rcbioassay data.
This study
differed from previous studies by using conservative weight of
evidence criteria to classify chemical carcinogens, data from 63
genetox and reprotox toxicological endpoints and a new statistical
parameter of correlation indicator (CI, the average of specificity
and positive predictivity) to identify good surrogate endpoints for
predicting carcinogenicity. Among 63 endpoints, results revealed
that carcinogenicity was well-correlated with certain tests for gene
mutation (n=8), in vivo clastogenicity (n=2), unscheduled DNA
synthesis assay (n=1) and reprotox (n=3).
The current FDA
regulatory battery of four genetox tests used to predict
carcinogenicity includes two tests with good correlation (gene
mutation in Salmonella and in vivo micronucleus) and two
tests with poor correlation (mouse lymphoma gene mutation and in
vitro chromosome aberrations) by our criteria.
The second
article II examines a novel method to identify carcinogens that
employed expanded data sets composed of in silico data pooled with
actual experimental genetic toxicity (genetox) and reproductive and
developmental toxicity (reprotox) data. We constructed 21 modules
using the MC4PC program including 13 of 14 (11 genetox and 3
reprotox) tests that we found correlated with results of rodent
carcinogenicity bioassays (rcbioassays) [Matthews et al., 2005b].
Each of the 21 modules was evaluated by cross-validation experiments
and those with high specificity (SP) and positive predictivity (PPV)
were used to predict activities of the 1442 chemicals tested for
carcinogenicity for which actual genetox or reprotox data were
missing. The expanded data sets had ~70% in silico data pooled with
~30% experimental data. Based upon SP and PPV, the expanded data
sets showed good correlation with carcinogenicity testing results
and had correlation indicator (CI, the average of SP and PPV) values
of 75.5 - 88.7%. Conversely, expanded data sets for 9 non-correlated
test endpoints were shown not to correlate with carcinogenicity
results (CI values <75%). Results also showed that when Salmonella
mutagenic carcinogens were removed from the 12 correlated, expanded
data sets, only 7 endpoints showed added value by detecting
significantly more additional carcinogens than non-carcinogens.
Updates
Pharm/Tox
Web Update.
Tom Papoian, Ph.D., DABT, from the Division of Cardiovascular
and Renal Products, presented a brief overview of the Pharmacology
and Toxicology Home Page, a CDER intranet site that serves as an
in-house resource of information related to the pharmacology and
toxicology of therapeutics. The site averages about 40,000 visits a
month and contains an extensive collection of documents, guidances,
tools, and links that are commonly used by pharm/tox reviewers.
Role and
Objectives of the Education Subcommittee of PTCC.
Aisar Atrakchi, Ph.D., from the Division of Psychiatry
Products and Co-Chair of the Educational Subcommittee of the
Pharmacology and Toxicology Coordinating Committee, said that
objectives of the subcommittee are to identify and prioritize the
specific scientific needs of the Pharm/Tox reviewers and to enhance
their scientific competency.
This is
accomplished through organizing formal courses, lecture series,
seminars or workshops on a specific topic and, coordinating with the
PTCC Retreat Subcommittee. This subcommittee is also responsible for
the scientific training of new reviewers as well as satisfying the
continuing educational needs of senior reviewers.
The
subcommittee is made up of a chair and a co-chair, voting members
who are pharmacologists/toxicologists from CDER and when possible an
executive secretary. Non-voting members include a representative
from the Office of Training and Communication and scientists from
other centers to encourage cross-center and inter-Agency
interactions.
Case Study
Tissue
Cross-Reactivity.
Melanie Hartsough, Ph.D., from the Division of Biologic
Oncology Products, presented tissue cross-reactivity data from a
pre-IND and subsequent IND submission that had problems with the
development of the immunohistochemistry (IHC) assay and the
interpretation of the results, with regard to relevant species.
She emphasized
that in some instances flexibility in the IHC design is needed in
order to obtain informative data and explained that the division had
agreed with the sponsor’s proposal to utilize an alternative
test-article, provided sufficient comparability to the material
intended for the clinic was established. Finally, she described the
thought process behind determining that there was no relevant
species to perform a toxicology study and the impact of this
decision on the initiation of the clinical trial.
Q and A on
Promotion Tracks.
Dave Morse,
Ph.D.,
a supervisory pharmacologist in the Division of Drug Oncology
Products, Bob Osterberg, Ph.D., Supervisory Pharmacologist in
Division of Anti-Infective and Ophthalmic Drugs, and Abby Jacobs,
Ph.D., Assoc. Dir. Pharm/Tox ONDIO conducted a 15 minute question
and answer period to discuss the promotion track programs available
to Pharm/Tox staff within the CDER.
The discussion
period for this topic was led by David Morse (Chair, CDER
Reviewer Career Path Committee - CRCP), Abby Jacobs and
Bob Osterberg (committee members of the Expert program).
Reviewers were encouraged to work with their immediate supervisors
in the evaluation of performance issues and identification of
regulatory and scientific issues that might contribute to their
promotion as well as on the preparation of promotion related
documents. Reviewers were directed to the CRCP and the Expert track
program intranet sites for detailed information on the preparation
of application materials for the various committees.
Retreat team
The
retreat was organized by pharm/tox reviewers and staff from various
divisions at CDER including: Jinhui Dou, Linda Fossom, Luan Lee,
John Leighton, Haleh Saber-Mahloogi (chair), Bob Osterberg,
Yanli Ouyang, Tom Papoian, Lilliam Rosario, Adele Seifried
and myself.
Gary
Bond is a pharmacologist in the Division of Pulmonary and Allergy
Products and would like to acknowledge the assistance of speakers
and retreat committee members in the preparation of this article.
Back to Contents
Next Page
Back
to Top
Back to About CDER
PDF requires the free Adobe
Acrobat Reader
Views and opinions expressed are those of the authors
and do not necessarily reflect official FDA or CDER policies. All
material in the Pike is in the public domain and may be
freely copied or printed. Deadline for submitting articles is the
15th of each month.
Date created: September 14, 2006 |